Sen. Orrin Hatch (R-Utah) and Rep. Greg Walden (R-Ore.) urged the Office of Management and Budget (OMB) to consider the potential fallout from the White House’s proposed rule that would remove drugmakers’ anti-kickback protections for prescription drug rebates.
Source: Drug Industry Daily